Long-term efficacy and safety of Vigabatrin in drug resistant epileptic patients

R. Manni, C. A. Galimberti, C. Zucca, L. Parietti, A. Iudice, E. Perucca, A. Tartara

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Twenty-five adult epileptic patients who had shown a satisfactory clinical response to add-on Vigabatrin (VGB) under placebo-controlled conditions continued on long-term treatment for up to 47 months (median 22 months). The initially favourable therapeutic response was generally maintained throughout the observation period with an oveall good clinical tolerability. No evidence of neurotoxicity was detected by multimodal evoked potentials monitoring.

Original languageEnglish
Title of host publicationBollettino - Lega Italiana contro l'Epilessia
Pages159-160
Number of pages2
Edition64
Publication statusPublished - 1988

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Long-term efficacy and safety of Vigabatrin in drug resistant epileptic patients'. Together they form a unique fingerprint.

Cite this